Publication | Closed Access

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program

Single CenterOncologyCompassionate Use ProgramSalvage TreatmentMolecular OncologyCancer TreatmentMedicineRadiation OncologyLung CancerCancer ResearchCancer Growth